Figure 2.

Incremental cost-effectiveness scatterplot and acceptability curve of RS-assay-guided therapy versus CCP-guided therapy for pre- and post-menopausal women. Sampling distributions and summary estimates of cost, efficacy, and variance were based on 1000 replicates.

Hannouf et al. BMC Cancer 2012 12:447   doi:10.1186/1471-2407-12-447
Download authors' original image